KR101958969B1 - A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant - Google Patents
A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant Download PDFInfo
- Publication number
- KR101958969B1 KR101958969B1 KR1020170163116A KR20170163116A KR101958969B1 KR 101958969 B1 KR101958969 B1 KR 101958969B1 KR 1020170163116 A KR1020170163116 A KR 1020170163116A KR 20170163116 A KR20170163116 A KR 20170163116A KR 101958969 B1 KR101958969 B1 KR 101958969B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- seaweed
- alcoholic
- plant
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 186
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 241001474374 Blennius Species 0.000 title claims abstract description 43
- 230000001476 alcoholic effect Effects 0.000 title claims abstract description 42
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- 241000196324 Embryophyta Species 0.000 claims abstract description 44
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 14
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims description 20
- 229940094952 green tea extract Drugs 0.000 claims description 19
- 235000020688 green tea extract Nutrition 0.000 claims description 19
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 240000006891 Artemisia vulgaris Species 0.000 claims description 9
- 241000195493 Cryptophyta Species 0.000 claims description 9
- 241000269837 Artemisia dubia Species 0.000 claims description 8
- 201000005917 gastric ulcer Diseases 0.000 claims description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 3
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 206010047700 Vomiting Diseases 0.000 claims description 3
- 230000008673 vomiting Effects 0.000 claims description 3
- 206010017856 Gastritis alcoholic Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 201000005988 alcoholic gastritis Diseases 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 241000195620 Euglena Species 0.000 claims 2
- 244000307700 Fragaria vesca Species 0.000 claims 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims 2
- 239000000419 plant extract Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 19
- 244000269722 Thea sinensis Species 0.000 abstract description 6
- 235000009569 green tea Nutrition 0.000 abstract description 4
- 241000392544 Dendropanax morbifer Species 0.000 abstract description 2
- 241001512722 Ecklonia cava Species 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 244000056139 Brassica cretica Species 0.000 abstract 1
- 235000003351 Brassica cretica Nutrition 0.000 abstract 1
- 235000003343 Brassica rupestris Nutrition 0.000 abstract 1
- 241000195474 Sargassum Species 0.000 abstract 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 235000010460 mustard Nutrition 0.000 abstract 1
- 239000013642 negative control Substances 0.000 description 28
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 26
- 239000007790 solid phase Substances 0.000 description 25
- 239000007791 liquid phase Substances 0.000 description 24
- 239000013641 positive control Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000843 powder Substances 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 14
- 102100021022 Gastrin Human genes 0.000 description 13
- 108010052343 Gastrins Proteins 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 13
- 229960001340 histamine Drugs 0.000 description 13
- 238000002156 mixing Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 231100000397 ulcer Toxicity 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000027119 gastric acid secretion Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 3
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 3
- 206010019133 Hangover Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
- 229960000620 ranitidine Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195940 Bryophyta Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241001071795 Gentiana Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
- 108010083687 Ion Pumps Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 235000013675 iodine Nutrition 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000199899 Alariaceae Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010001623 Alcoholic hangover Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 240000006053 Garcinia mangostana Species 0.000 description 1
- 235000017048 Garcinia mangostana Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206671 Gelidium amansii Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000199900 Laminariales Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000195473 Sargassum fulvellum Species 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047627 Vitamin deficiencies Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003653 coastal water Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000010459 dolomite Substances 0.000 description 1
- 229910000514 dolomite Inorganic materials 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- KQFUCKFHODLIAZ-UHFFFAOYSA-N manganese Chemical compound [Mn].[Mn] KQFUCKFHODLIAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940105902 mint extract Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229920001339 phlorotannin Polymers 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 알코올성 위장질환을 개선, 예방 또는 치료할 수 있도록 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유하는 조성물에 관한 것이다.The present invention relates to a composition containing an algae extract and a plant complex extract as active ingredients so as to improve, prevent or treat an alcoholic gastrointestinal disorder.
숙취란 취할 때까지 술을 마신 사람들이 경험하는 현상으로 빈번히 나타나면서도 유쾌하지 못한 신체적, 정신적 증상을 말한다. 원인으로는 알코올 및 그 중간 대사산물인 아세트알데히드의 독성, 탈수, 흡수 장애로 인한 영양소의 결핍(혈당, 무기질 및 비타민 결핍)으로 알려져 있다. 숙취의 정도는 개인에 따른 편차(유전적 소양), 환경상태(영양상태, 운동상태, 탈수 정도, 건강상태 등)에 따라 그 차이가 매우 심하게 나타난다. 대표적인 증상으로는 목마름, 구토, 피로, 현기증, 두통 등이 있고, 이러한 요소들이 복합적으로 작용하기도 한다.Hangover is a phenomenon experienced by people who have drunk until they are drunk, but it often refers to unpleasant physical and mental symptoms. The cause is known as the lack of nutrients (blood sugar, minerals and vitamin deficiencies) due to the toxicity, dehydration and absorption of alcohol and its intermediate metabolite, acetaldehyde. The degree of hangover is very different according to individual variation (genetic inheritance), environmental condition (nutrition status, exercise status, degree of dehydration, health status, etc.). Typical symptoms include thirst, vomiting, fatigue, dizziness, and headache.
알코올은 간에서 알코올 데하이드로게나제 (ADH)와 조효소인 NAD+에 의해 숙취의 원인물질로 알려진 아세트알데히드로 산화되며, 알데히드 데하이드로게나제 (ALDH)와 NAD+에 의해서 아세트산으로 분해된다.Alcohol is oxidized to acetaldehyde, known as the causative agent of hangover, by the alcoholic dehydrogenase (ADH) and coenzyme NAD + in the liver, and is degraded to acetic acid by aldehyde dehydrogenase (ALDH) and NAD +.
또한, 사이토크롬 P-450 type 2E1(CYP2E1)과 카탈라아제에 의해서도 아세트알데히드로 산화되는데, 아세트알데히드와 아세트산은 지질 과산화반응 등을 통해 세포독성, 두통이나 복통, 삼투압 변화에 따른 탈수현상 등을 일으킨다. In addition, cytochrome P-450 type 2E1 (CYP2E1) and catalase also oxidize to acetaldehyde. Acetaldehyde and acetic acid cause cytotoxicity through lipid peroxidation, dehydration due to headache, abdominal pain, and osmotic changes.
또한, 현대인의 주요 질환 중 하나인 소화성 위궤양(peptic ulcers)은 점막이 위산(gastric HCl)과 펩신에 잠겨 있는 부위의 손상을 의미하는 것으로, 이 부위는 정상적으로 점막 세포가 분비하는 뮤신에 의해 덮여있다. 따라서 위산 분비 촉진, 펩신의 침습에 대항하는 뮤신 층의 약화 혹은 고갈, 국소 혈액순환 장애, 세포손상 및 염증반응 등 다양한 원인에 의해 위 점막 미란(erosions)과 궤양이 유발된다.In addition, peptic ulcers, one of the major diseases of modern humans, imply that the mucosa is damaged by gastric HCl and pepsin, which is normally covered by mucin secreted by mucous cells . Therefore, gastric mucosal erosions and ulcers are caused by various causes such as stimulation of gastric acid secretion, weakening or depletion of mucin layer against pepsin invasion, disturbance of blood circulation, cell damage and inflammation reaction.
그러므로 위궤양을 일으키는 원인물질로는 뮤신 층을 강화시키고 국소 혈행을 원활하게 해 주는 PGs을 생성하는 효소인 사이클로옥시게나제(COX)를 억제하는 비스테로이드성 소염제(NSAIDs) 등의 약물, 심리적 스트레스, 위산과다분비 및 저류, 위장운동성 증가 및 아세트산 축적, 헬리코박터 파이로리와 같은 세균감염 등을 들 수 있다.Therefore, gastric ulcers are caused by drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX), an enzyme that produces PGs that strengthens the mucin layer and smoothes local blood circulation, Gastric acid secretion and accumulation, bacterial infections such as Helicobacter pylori, and the like.
특히, 고농도의 알코올은 위 점막의 울혈을 초래하여 직접적인 출혈 및 괴사를 유발함은 물론 라디칼 반응에 따른 지질 과산화반응도 관여하는 것으로 알려져 있다.In particular, high concentrations of alcohol are known to cause congestion of the gastric mucosa, leading to direct hemorrhage and necrosis, as well as lipid peroxidation through radical reactions.
위궤양 치료제로는 벽세포로부터의 산 분비를 차단하는 수소 이온 펌프 억제제, 제산제(antacids), 산 분비를 촉진시키는 히스타민의 수용체 차단제(H2-antagonists), 뮤신층 강화제인 PGs와 그 유도체, 그리고 헬리코박터파이로리를 근절할 수 있는 항생제류가 대표적이다(Wallace와 Granger, 1996; Neal, 2003).Anti-gastric ulcers include hydrogen ion pump inhibitors, antacids, and H2-antagonists to block acid secretion from wall cells, histamine (H2-antagonists) that promote acid secretion, PGs and their derivatives as a mucin-layer enhancer, and Helicobacter pylori (Wallace and Granger, 1996; Neal, 2003).
알코올성 숙취와 위궤양은 현대인에 있어 빼놓을 수 없는 질환 중 하나로 많은 사람들이 겪고 있다. 특히 사회적 스트레스에 더해 빈번한 알코올의 섭취는 심각한 위궤양과 함께 간질환을 동반하는 경우가 많아 이를 개선하기 위한 많은 의약품과 건강기능성식품들이 판매되고 있다. 즉, ADH 및 ALDH를 활성화시켜 알코올 혈중농도를 낮추기 위한 노력이 집중적으로 이루어지고 있다. 하지만 단기간의 복용으로 효소를 활성화시켜 유의한 해독효과를 나타내는 효과적인 물질은 거의 찾아 볼 수 없다. Alcoholic hangover and stomach ulcers are one of the most common diseases in modern people. Especially, frequent consumption of alcohol in addition to social stress is accompanied with severe gastric ulcer and liver disease, and many medicines and health functional food products are being sold to improve it. That is, efforts to lower the alcohol blood concentration by activating ADH and ALDH have been intensively performed. However, there are few effective substances that activate the enzyme by a short-term dose and thus exhibit significant detoxifying effects.
특히, 수소 이온 펌프 억제제인 판토프라졸과 같은 위궤양 치료제의 경우에도 다른 원인에 의한 위궤양에는 효과적이지만 알코올성 위궤양에는 효과가 미약한 것으로 알려져 있다(Cao 등, 2004).In particular, the treatment of gastric ulcer, such as pantoprazole, which is a hydrogen ion pump inhibitor, is effective for gastric ulcers caused by other causes, but it is not effective for alcohol ulcers (Cao et al., 2004).
따라서, 생약 추출물 또는 인공제제 원료를 이용한 알코올성 위장질환용 식품이나 의약품이 개발되어 유통되고 있으나, 이들은 약효가 다소 인정되기는 해도 만족할만한 수준에 미치지 못하므로 부작용이 없으면서 효과가 충분히 인정되는 새로운 알코올성 위장질환 개선, 예방 또는 치료가 가능한 물질의 개발이 요구되고 있다.Therefore, foods or medicines for alcoholic gastrointestinal diseases using herbal medicine extracts or artificial preparations have been developed and distributed. However, they have not been satisfactorily satisfactory even though their efficacy is somewhat recognized. Therefore, new alcoholic gastrointestinal diseases There is a demand for development of a substance capable of improving, preventing, or treating cancer.
본 발명의 목적은 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유하여 알코올성 위장질환을 예방 또는 치료할 수 있는 약학 조성물을 제공하는데 있다.It is an object of the present invention to provide a pharmaceutical composition containing an algae complex extract and a plant complex extract as an active ingredient to prevent or treat alcoholic gastrointestinal diseases.
또한, 본 발명의 다른 목적은 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유하여 알코올성 위장질환을 개선 또는 예방할 수 있는 식품 조성물을 제공하는데 있다.Another object of the present invention is to provide a food composition containing as an active ingredient an algae complex extract and a plant complex extract capable of alleviating or preventing an alcoholic gastrointestinal disorder.
상기한 목적을 달성하기 위한 본 발명의 알코올성 위장질환을 예방 또는 치료할 수 있는 약학 조성물은 감태 추출물, 우뭇가사리 추출물, 톳 추출물, 모자반 추출물 및 돌미역 추출물을 포함하는 해조류 복합추출물; 및 In order to accomplish the above object, the present invention provides a pharmaceutical composition capable of preventing or treating alcoholic gastrointestinal diseases, which comprises at least one extract selected from the group consisting of Ganoderma lucidum extract, Mugwort extract, Capsicum annuum extract, And
황칠 추출물 및 녹차 추출물을 포함하는 식물 복합추출물;을 포함하는 혼합물을 유효성분으로 함유할 수 있다.An extract of a plant complex containing a green tea extract and a green tea extract, as an active ingredient.
상기 해조류 복합추출물은 감태 추출물 25 내지 40 중량%, 우뭇가사리 추출물 1 내지 10 중량%, 톳 추출물 25 내지 40 중량%, 모자반 추출물 25 내지 35 중량% 및 돌미역 추출물 1 내지 10 중량%를 포함할 수 있다.The seaweed complex extract may contain 25 to 40 wt% of a gentian extract, 1 to 10 wt% of a mugwort extract, 25 to 40 wt% of a mugwort extract, 25 to 35 wt% of a mugwort extract, and 1 to 10 wt% of a mugwort extract .
상기 식물 복합추출물은 황칠 추출물과 녹차 추출물은 1 : 0.7-1.3의 중량비로 혼합될 수 있다.The plant complex extract may be mixed with a mixture of Huangchil extract and green tea extract at a weight ratio of 1: 0.7-1.3.
상기 해조류 복합추출물과 식물 복합추출물은 1 : 5 내지 90의 중량비로 혼합될 수 있다.The algae complex extract and the plant complex extract may be mixed at a weight ratio of 1: 5 to 90.
상기 감태 추출물, 우뭇가사리 추출물, 톳 추출물, 모자반 추출물, 돌미역 추출물, 황칠 추출물 및 녹차 추출물은 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로 추출된 것일 수 있다.The mint extract, mugwort extract, mangosteen extract, manganese manganese extract, dolomite extract, Huangchil extract and green tea extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
상기 알코올성 위장질환은 알코올에 의한 메스꺼움, 구토, 복통, 소화불량, 알코올성 위염 및 알코올성 위궤양 중에서 선택된 하나 이상인 것일 수 있다.The alcoholic gastrointestinal disorder may be one or more selected from nausea, vomiting, abdominal pain, indigestion, alcoholic gastritis and alcoholic gastric ulcer caused by alcohol.
또한, 상기한 다른 목적을 달성하기 위한 본 발명의 알코올성 위장질환을 개선 또는 예방할 수 있는 식품 조성물은 감태 추출물, 우뭇가사리 추출물, 톳 추출물, 모자반 추출물 및 돌미역 추출물을 포함하는 해조류 복합추출물; 및 In another aspect of the present invention, there is provided a food composition capable of improving or preventing alcoholic gastrointestinal diseases, which comprises at least one of algae extracts including Ganoderma lucidum extract, Mugwort extract, Top extract, Mungbean extract, And
황칠 추출물 및 녹차 추출물을 포함하는 식물 복합추출물;을 포함하는 혼합물을 유효성분으로 함유할 수 있다.An extract of a plant complex containing a green tea extract and a green tea extract, as an active ingredient.
본 발명의 알코올성 위장질환의 개선, 예방 또는 치료용 조성물은 알코올성 위장질환으로 인한 병리학적 소견을 완화시킬 수 있으므로 알코올성 위장질환의 예방 또는 치료에 현저한 효과가 있다.The composition for improving, preventing or treating alcoholic gastrointestinal diseases of the present invention can alleviate the pathological findings due to alcoholic gastrointestinal diseases and thus has a remarkable effect in the prevention or treatment of alcoholic gastrointestinal diseases.
또한, 본 발명은 천연물질인 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 포함하여 부작용이 없으며 저렴하므로 알코올성 위장질환에 장기적으로 사용할 수 있다.In addition, the present invention can be used for alcoholic gastrointestinal diseases for a long period of time because it has no side effects and contains a natural extract of a seaweed compound complex and a plant complex extract as effective ingredients.
도 1은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 궤양 인덱스를 나타낸 그래프이다.
도 2는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군을 촬영한 사진이다.
도 3은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 히스타민(Histamine) 농도를 나타낸 그래프이다.
도 4는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 가스트린(Gastrin) 농도를 나타낸 그래프이다.
도 5는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 IL-1β 농도를 나타낸 그래프이다.
도 6은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 TNF-α 농도를 나타낸 그래프이다.FIG. 1 is a graph showing the ulcer indexes of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
FIG. 2 is a photograph of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
FIG. 3 is a graph showing the histamine concentrations of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
FIG. 4 is a graph showing the concentration of Gastrin in the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
FIG. 5 is a graph showing the IL-1? Concentrations in the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
FIG. 6 is a graph showing the TNF-.alpha. Concentrations of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
본 발명은 알코올성 위장질환을 개선, 예방 또는 치료할 수 있도록 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유하는 조성물에 관한 것이다.
The present invention relates to a composition containing an algae extract and a plant complex extract as active ingredients so as to improve, prevent or treat an alcoholic gastrointestinal disorder.
이하, 본 발명을 상세하게 설명한다. Hereinafter, the present invention will be described in detail.
본 발명의 알코올성 위장질환을 개선, 예방 또는 치료할 수 있는 조성물은 해조류 복합추출물 및 식물 복합추출물을 유효성분으로 함유한다.The composition capable of improving, preventing or treating the alcoholic gastrointestinal disease of the present invention contains the seaweed complex extract and the plant complex extract as an active ingredient.
상기 해조류 복합추출물은 감태 추출물, 우뭇가사리 추출물, 톳 추출물, 모자반 추출물 및 돌미역 추출물을 포함하며; 상기 식물 복합추출물은 황칠 추출물 및 녹차 추출물을 포함한다.The above-mentioned seaweed compound complex extracts include Ganoderma lucidum extract, Mugwort extract, Chrysanthemum morifolium extract, Mulberry leaf extract and Strawberry Seed Extract; The plant complex extract includes Huangchil extract and green tea extract.
상기 감태(Ecklonia cava)는 갈조식물 다시마목 미역과의 해조류로, 한국, 일본 등지에 분포한다. 상기 감태는 후코이단과 플로로탄닌 성분을 함유하고 있으며, 상기 성분들은 항산화, 항암, 항염, 노화억제 및 고혈압억제 등에 우수한 것으로 알려져 있다. Ecklonia cava is a marine algae with brown algae, and is distributed in Korea and Japan. The above menthol contains fucoidan and phlorotannin components, and these components are known to be superior to antioxidants, anti-cancer, anti-inflammation, anti-aging and hypertension inhibition.
상기 감태는 추출물 형태로서 25 내지 40 중량%, 바람직하게는 30 내지 35 중량%로 사용된다. 감태 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The menthol is used in the form of an extract in an amount of 25 to 40% by weight, preferably 30 to 35% by weight. If the content of gentian extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be deteriorated.
또한, 상기 우뭇가사리(Gelidium amansii)는 우뭇가사리과에 속하는 홍조류로서, 단백질 4.2%, 지방 0.2%, 탄수화물 18.5%, 섬유질 3.0%, 무기질 3.8%를 함유한다. 상기 우뭇가사리는 식용, 약용, 연구용, 공업용 등의 용도로 다양하게 활용되고 있으며, 식용 첨가물로서 영양적으로 많은 양의 탄수화물을 지니고 있고, 철분과 칼슘을 상당량 함유하고 있으며, 비타민A가 특히 많다.The above-mentioned Gelidium amansii is a red alga belonging to the mugwort family. It contains 4.2% protein, 0.2% fat, 18.5% carbohydrate, 3.0% fiber and 3.8% inorganic. The mugwort is widely used for various purposes such as edible, medicinal, research, and industrial applications. It has a nutritious amount of carbohydrate as an edible additive, contains a large amount of iron and calcium, and has a particularly large amount of vitamin A.
상기 우뭇가사리는 추출물 형태로서 1 내지 10 중량%, 바람직하게는 2 내지 5 중량%로 사용된다. 우뭇가사리 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The extract is used in an amount of 1 to 10% by weight, preferably 2 to 5% by weight. If the content of Leucocephalus extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be deteriorated.
또한, 상기 톳(Hizikia fusiforme)은 모자반과에 속하는 갈조류로, 뿌리는 나뭇가지 모양이고 줄기는 원주형이며 잎은 베 짜는 북 또는 방망이 모양이고 곁가지는 엽액에 붙어서 난다. 우리나라의 중부 이남에 분포하고 특히 제주도와 서남해안에서 많이 생산되며, 칼슘, 요오드, 철 등의 무기염류가 많이 포함되어 있다.In addition, Hizikia fusiforme is a brown algae belonging to the moth, and its roots are in the shape of branches, the stem is columnar, the leaves are in the shape of a drum or bat, and the branches are attached to the leaf. It is distributed in the southern part of Korea, especially in Jeju and South western coasts. It contains many inorganic salts such as calcium, iodine and iron.
상기 톳은 추출물 형태로서 25 내지 40 중량%, 바람직하게는 30 내지 35 중량%로 사용된다. 톳 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The extract is used in an amount of 25 to 40% by weight, preferably 30 to 35% by weight. If the content of the top extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be deteriorated.
또한, 상기 모자반(Sargassum fulvellum)은 모자반과에 속하는 갈조류의 하나로, 연안에 나며 녹갈색으로 톳과 비슷한 모양을 하고 있다. 일반성분은 단백질 1.85%, 지방 0.2%, 탄수화물 5.2%, 섬유 1.5%, 무기질 5.1%이며, 이중 칼슘의 함량이 많다.In addition, Sargassum fulvellum is one of the brown algae belonging to the mulberry family and has a shape similar to a greenish brown color in the coast. The general ingredients are 1.85% protein, 0.2% fat, 5.2% carbohydrate, 1.5% fiber and 5.1% inorganic, with a high content of calcium.
상기 모자반은 추출물 형태로서 25 내지 35 중량%, 바람직하게는 30 내지 35 중량%로 사용된다. 모자반 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The moth is used in the form of an extract in an amount of 25 to 35% by weight, preferably 30 to 35% by weight. If the content of mung bean extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be decreased.
또한, 상기 돌미역은 다시마목(Laminariales) 미역과(Alariaceae)에 속하는 1년생 대형 조류로서 울릉도 청정해역 해안가 바위에서 자연 생산되며, 풍부한 단백질, 비타민, 미네랄, 칼슘, 요오드 등의 영양소가 다양하게 함유되어 있다. In addition, the dolm is the one year old algae belonging to the Laminariales seaweed (Alariaceae). It is naturally produced in the coastal rocks of Ulleungdo's coastal waters, and rich in nutrients such as protein, vitamins, minerals, calcium and iodine .
상기 돌미역은 추출물 형태로서 1 내지 10 중량%, 바람직하게는 2 내지 5 중량%로 사용된다. 돌미역 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The above-mentioned seaweed is used as an extract form in an amount of 1 to 10% by weight, preferably 2 to 5% by weight. If the content of the extract of the stalwil waxy is outside the above range, the efficacy against alcoholic gastrointestinal diseases may be deteriorated.
상기 감태, 우뭇가사리, 톳, 모자반 및 돌미역은 각각 추출용매와 1 : 5 내지 25, 바람직하게는 1 : 8 내지 15의 중량비로 혼합하여 80 내지 110 ℃에서 추출함으로써 추출물을 제조한다. 상기 감태, 우뭇가사리, 톳, 모자반 및 돌미역 각각과 추출용매의 중량비가 상기 범위를 벗어나는 경우에는 추출물에 유효성분이 적은 양으로 추출될 수 있다. 또한, 추출온도가 상기 하한치 미만인 경우에는 유효성분이 추출되지 않을 수 있으며, 상기 상한치 초과인 경우에는 유효성분이 적은 양으로 추출될 수 있다.The extracts are prepared by mixing the extracts with the extraction solvent at a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, and extracting at 80 to 110 ° C. When the weight ratio of each of the above extracts, extracts, mosses, mosses, and seaweed extracts and the extraction solvent is out of the above range, the extract may be extracted in a small amount with an effective amount. If the extraction temperature is lower than the lower limit value, the effective ingredient may not be extracted. If the extraction temperature is higher than the upper limit value, the effective ingredient may be extracted in a smaller amount.
상기 추출물을 추출하는 추출용매로는 알코올성 위장질환의 개선, 예방 또는 치료에 바람직하게 작용할 수 있도록 물, 탄소수 1 내지 4의 저급알코올, 또는 이들의 혼합용매를 사용할 수 있다. 상기 혼합용매로는 특별히 한정하는 것은 아니지만, 바람직하게는 20 내지 80 부피%의 메탄올, 에탄올, 부탄올 또는 프로판올 수용액, 더욱 바람직하게는 60 내지 80 부피%의 에탄올 수용액으로 추출된 추출물을 들 수 있다.As the extraction solvent for extracting the extract, water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be used so as to favorably improve, prevent or treat alcoholic gastrointestinal diseases. The mixed solvent is not particularly limited, but an extract obtained by extracting with 20 to 80% by volume of an aqueous solution of methanol, ethanol, butanol or propanol, more preferably 60 to 80% by volume of ethanol is preferable.
또한, 상기 황칠(Dendropanax morbifera LEV.)은 두릅나무과에 속하는 난대성 상록교목으로, 우리나라의 남부 해안 지역과 제주도에서 자생하며, 겨울에도 낙엽이 지지 않는 수종으로 수피에 상처를 주면 황색의 수지액이 나오는데 이것을 황칠이라고 한다. 황칠 안에 들어 있는 정유의 주성분은 세스퀴테르펜(sesqui-terpene)이며, 그밖에 알코올, 에스테르 등이 함유되어 있다. 또한, 황칠나무는 번열 제거, 술 해독, 안질 및 황달 치료, 나병에 효과가 있으며 인체에 무해하다는 기록도 전해지고 있다 (이시진, 본초강목, 중국문광도서, 1590).The dandelion (Dendropanax morbifera LEV.) Is an evergreen tree belonging to Araliaceae. It is native to the southern coast of Korea and Jeju Island. It is a species that does not fall down in winter. If it bruises the bark, This is called Huangchil. The main ingredient of the essential oil contained in Huangchil is sesqui-terpene, and other alcohol and ester. In addition, it has been reported that Hwangchil is effective in eliminating burning, alcoholic detoxification, treatment of eye and jaundice, leprosy and harmless to the human body (Ishinjin, Bascho Gangmok, Munkwang Book, 1590).
상기 황칠은 추출물 형태로서 40 내지 60 중량%로 사용된다. 황칠 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다. The yellowing is used in an amount of 40 to 60% by weight in the form of an extract. If the content of Huangchil extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be deteriorated.
또한, 상기 녹차(Camellia sinensis O.Kuntge)는 경남, 전남의 남해안지역의 비교적 따뜻한 곳에서 자라는 여러해살이 상록교목으로, 잎은 단단하고 약간 두꺼우며 표면에 광택이 있다. 콜레스테롤과 혈당을 낮추는 효과가 있으며, 항산화작용을 한다.Also, the green tea (Camellia sinensis O.Kuntge) is a perennial evergreen arboreous tree that grows in a relatively warm place on the southern coast of Kyungnam and Jeonnam. Its leaves are hard, slightly thick and glossy on the surface. It lowers cholesterol and blood sugar and has antioxidant activity.
상기 녹차는 추출물 형태로서 40 내지 60 중량%로 사용된다. 녹차 추출물의 함량이 상기 범위를 벗어난 경우에는 알코올성 위장질환에 대한 효능이 저하될 수 있다.The green tea is used in an amount of 40 to 60% by weight as an extract. If the content of green tea extract is out of the above range, the efficacy against alcoholic gastrointestinal diseases may be decreased.
바람직하게, 상기 황칠 추출물과 녹차 추출물은 1 : 0.7-1.3의 중량비로 혼합되는데, 상기 황칠 추출물을 기준으로 녹차 추출물의 함량이 상기 하한치 미만인 경우에는 효능이 저하될 수 있으며, 상기 상한치 초과인 경우에는 관능성이 저하될 수 있다. Preferably, the green tea extract and the green tea extract are mixed at a weight ratio of 1: 0.7-1.3. When the content of the green tea extract is lower than the lower limit, the efficacy may be lowered. If the content is higher than the upper limit, The functionality may be lowered.
상기 황칠 및 녹차는 각각 상기 해조류 복합추출물을 추출하는 방법과 동일한 방법으로 추출될 수 있다.The above yellowtail and green tea can be extracted in the same manner as the method of extracting the above-mentioned seaweed complex extract.
본 발명의 해조류 복합추출물과 식물 복합추출물은 1 : 5 내지 90의 중량비, 바람직하게는 1 : 11 내지 80의 중량비로 혼합된다. 해조류 복합추출물을 기준으로 식물 복합추출물의 함량이 상기 하한치 미만인 경우에는 알코올성 위장질환에 대한 개선, 예방 또는 치료 효과가 저하될 수 있으며, 상기 상한치 초과인 경우에는 텁텁하고 관능성이 저하될 수 있다.The seaweed extract of the present invention and the plant combination extract of the present invention are mixed at a weight ratio of 1: 5 to 90, preferably 1: 11 to 80. If the content of the plant complex extract is lower than the lower limit, the effect of improving, preventing or treating alcoholic gastrointestinal diseases may be deteriorated. If the content of the plant complex extract is lower than the upper limit, it may be deteriorated.
본 명세서에서 감태, 우뭇가사리, 톳, 모자반, 돌미역, 황칠 및 녹차를 언급하면서 사용되는 용어 '추출물'은 추출용매를 처리하여 얻은 조추출물뿐만 아니라 추출물의 가공물도 포함한다. 예를 들어, 본 발명의 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The term "extract" used in the present specification refers to the extracts of the extract as well as the crude extract obtained by treating the extraction solvent. For example, the extract of the present invention can be prepared in a powder state by an additional process such as vacuum distillation and freeze-drying or spray-drying.
또한, 본 발명의 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물은 광의로는 해조류 복합추출물 및 식물 복합추출물이 혼합된 혼합물을 동물에게 투여할 수 있도록 제형화된 해조류 복합추출물 및 식물 복합추출물이 혼합된 혼합물의 가공물, 예컨대, 해조류 복합추출물 및 식물 복합추출물이 혼합된 혼합물 분말도 포함하는 의미를 갖는다. 비록 본 발명에서 해조류 복합추출물 및 식물 복합추출물이 혼합된 혼합물의 추출물로 실험을 진행하긴 하였으나, 해조류 복합추출물 및 식물 복합추출물이 혼합된 혼합물의 가공물과 같은 형태로도 목적하는 효과를 달성할 수 있음은 당업자라면 예상 가능할 것이다.In addition, the extract of the seaweed complex extract and the plant complex extract of the present invention may be mixed with the seaweed complex extract and the plant complex extract formulated so that a mixture of the seaweed complex extract and the plant complex extract may be administered to the animal But also a mixture powder of a mixture of the mixture, for example, a seaweed complex extract and a plant complex extract. Although the present invention has been carried out with an extract of a mixture of a seaweed compound complex and a plant complex extract, the desired effect can be achieved even in the form of a mixture of a mixture of a seaweed compound complex and a plant complex extract Would be predictable by those skilled in the art.
한편, 본 명세서에서 용어 '유효성분으로 함유하는'이란 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 일예로, 상기 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물은 10 내지 1500 ㎍/㎖, 바람직하게는 100 내지 1000 ㎍/㎖의 농도로 사용된다. 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.
As used herein, the term " comprising as an active ingredient " means an amount sufficient to attain the efficacy or activity of the extract mixed with the seaweed complex extract and the plant complex extract. For example, the extract obtained by mixing the seaweed complex extract and the plant complex extract is used at a concentration of 10 to 1500 μg / ml, preferably 100 to 1000 μg / ml. Since the extracts mixed with seaweed extracts and plant complex extracts have no adverse effects on the human body even when they are administered in an excessive amount as natural products, the quantitative upper limit of the extracts obtained by mixing the seaweeds complex extract and plant combination extract contained in the composition of the present invention As shown in FIG.
본 발명의 약제학적 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention can be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, A lubricant or a flavoring agent can be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.
상기 약제학적 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.The pharmaceutical composition may be in the form of granules, powders, tablets, coated tablets, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile water and sterile water suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약제학적 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the composition can be administered by intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, etc., .
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약제학적 조성물의 1일 투여량은 0.001-10 g/㎏이다.The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
본 발명의 약제학적 조성물은 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention can be prepared in unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
또한, 본 발명은 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 유효성분으로 함유하는 알코올성 위장질환의 개선, 예방 또는 치료용 식품 조성물을 제공한다.The present invention also provides a food composition for improving, preventing or treating an alcoholic gastrointestinal disorder, which comprises an extract of a mixture of a seaweed compound complex and a plant complex extract as an active ingredient.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 알코올 음료류, 과자류, 다이어트바, 유제품, 육류, 초코렛, 피자, 라면, 기타 면류, 껌류, 아이스크림류, 비타민 복합제, 건강보조식품류 등이 있다.The food composition according to the present invention can be formulated in the same manner as the above pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .
본 발명의 식품 조성물은 유효성분으로서 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 본 발명의 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may contain, as an active ingredient, not only an extract obtained by mixing a seaweed complex extract and a plant complex extract but also a component that is ordinarily added during the manufacture of a food, for example, a protein, a carbohydrate, a fat, Seasoning and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared as a drink and a beverage, the extract of the seaweed complex and the plant complex extract of the present invention may contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, And the like.
본 발명은 상기 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 유효성분으로 포함하는 알코올성 위장질환의 개선, 예방 또는 치료용 식품 조성물을 포함하는 건강기능식품을 제공한다. 건강기능식품이란, 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.The present invention provides a health functional food comprising a food composition for improving, preventing or treating an alcoholic gastrointestinal disorder, which comprises an extract obtained by mixing the above-mentioned seaweed complex extract and plant complex extract as an active ingredient. The health functional food refers to a food prepared by adding an extract obtained by mixing a seaweed compound complex and a plant complex extract to a food material such as a beverage, a tea, a spice, a gum or a confectionery, or by encapsulating, pulverizing or suspending However, unlike general medicines, it has the advantage that there are no side effects that may occur when a drug is taken for a long time using the food as a raw material. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The amount of the extract of the combination of the seaweed compound complex and the plant complex extract in such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added but may be added within a range that does not deteriorate the original taste of the food And is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight based on the target food. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.
또한, 본 발명은 알코올성 위장질환의 개선, 예방 또는 치료용 의약 또는 식품의 제조를 위한 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물의 용도를 제공한다. 상기한 바와 같이 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물은 알코올성 위장질환의 개선, 예방 또는 치료를 위한 용도로 이용될 수 있다.In addition, the present invention provides the use of an extract obtained by mixing a seaweed complex extract and a plant complex extract for the production of a medicament or food for the improvement, prevention or treatment of alcoholic gastrointestinal diseases. As described above, the extract obtained by mixing the seaweed compound complex and the plant complex extract can be used for the improvement, prevention or treatment of alcoholic gastrointestinal diseases.
또한, 본 발명은 포유동물에게 유효량의 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 투여하는 것을 포함하는 알코올성 위장질환의 개선, 예방 또는 치료 방법을 제공한다.The present invention also provides a method of improving, preventing or treating an alcoholic gastrointestinal disorder, comprising administering to a mammal an effective amount of an extract of a combination of a seaweed compound extract and a plant complex extract.
여기에서 사용된 용어 "포유동물"은 치료, 관찰 또는 실험의 대상인 포유동물을 말하며, 바람직하게는 인간을 말한다.The term " mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.
여기에서 사용된 용어 "유효량"은 연구자, 수의사, 의사 또는 기타 임상의에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양을 의미하는 것으로, 이는 해당 질환 또는 장애의 증상의 완화를 유도하는 양을 포함한다. 본 발명의 유효 성분에 대한 유효량 및 투여횟수는 원하는 효과에 따라 변화될 수 있다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 본 발명의 예방, 치료 또는 개선 방법에 있어서, 성인의 경우, 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 1일 1회 내지 수회 투여시, 0.001 g/kg 내지 10 g/kg의 용량으로 투여하는 것이 바람직하다.As used herein, the term " effective amount " refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. The effective amount and the administration frequency for the active ingredient of the present invention can be changed according to the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the prevention, treatment or improvement method of the present invention, in the case of an adult, the extract mixed with seaweed extract and plant complex extract is administered at a dose of 0.001 g / kg to 10 g / kg once or several times a day .
본 발명의 치료방법에서 해조류 복합추출물 및 식물 복합추출물이 혼합된 추출물을 유효 성분으로 포함하는 조성물은 경구, 직장, 정맥내, 동맥내, 복강내, 근육내, 흉골내, 경피, 국소, 안구내 또는 피내 경로를 통해 통상적인 방식으로 투여할 수 있다.
In the therapeutic method of the present invention, the composition comprising the extract of the seaweed compound complex and the plant complex extract as an active ingredient can be administered orally, rectally, intravenously, intraarterially, intraperitoneally, intramuscularly, intrasternally, transdermally, Or via the intradermal route in a conventional manner.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.
실시예Example 1 내지 20. 해조류 복합추출물+식물 복합추출물 1 to 20. Seaweed complex extract + plant complex extract
감태 추출물, 우뭇가사리 추출물, 톳 추출물, 모자반 추출물, 돌미역 추출물을 포함하는 해조류 복합추출물;과 황칠 추출물 및 녹차 추출물을 포함하는 식물 복합추출물;을 포함하는 조성물을 하기 표 1의 제조 비율에 따라 제조하였다. 이때 식물 복합추출물은 황칠 추출물과 녹차 추출물을 50 중량%씩 동일한 양으로 첨가하였다.A composition comprising a seaweed extract, a green tea extract, a green tea extract, and a green tea extract, was prepared according to the production ratios shown in Table 1 below . At this time, the plant complex extract was added in an amount of 50 wt% each of Huangchil extract and green tea extract.
<시험예><Test Example>
시험예 1. 항산화 측정Test Example 1. Antioxidant measurement
상기 실시예 1 내지 20에 따라 제조된 조성물에 대한 DPPH 자유 라디칼 소거능 측정을 통해 항산화 효과를 평가함으로써 유효성분의 배합비율을 선정하였다.DPPH free radical scavenging activity of the compositions prepared according to Examples 1 to 20 was measured to determine the compounding ratio of the active ingredients by evaluating the antioxidative effect.
에탄올에 용해시킨 0.2 mM DPPH(1,1-diphenyl-2-picrylhydrazyl) 용액 950 ㎖에 상기 실시예 1 내지 20의 조성물을 각각 DMSO(dimethylsulfoxide)에 100 ㎕/㎖로 희석한 용액 50 ㎕를 가한 후 실온에서 30분간 incubation 후 517 ㎚에서 흡광도를 측정하였다. 항산화 활성은 하기 [수학식 1]로 계산하였다.50 μl of a solution prepared by diluting each of the compositions of Examples 1 to 20 with 100 μl / ml of DMSO (dimethyl sulfoxide) was added to 950 ml of a 0.2 mM DPPH (1,1-diphenyl-2-picrylhydrazyl) solution dissolved in ethanol After incubation at room temperature for 30 minutes, the absorbance was measured at 517 nm. The antioxidant activity was calculated by the following formula (1).
[수학식 1][Equation 1]
항산화 활성(%) = {1-(시료 첨가군 흡광도/시료 무첨가군 흡광도)}X00 (%)Antioxidant activity (%) = {1- (absorbance of sample group / absorbance of group without sample)} X00 (%)
위 표 2에 나타낸 바와 같이, 본 발명의 실시예 6, 7, 10, 11, 14 및 15의 조성물은 항산화 활성이 대략 80% 내외로 우수하며, 그외 조성물의 경우에는 이에 비해 낮은 항산화 활성을 보이는 것을 확인하였다. As shown in Table 2 above, the compositions of Examples 6, 7, 10, 11, 14 and 15 of the present invention exhibited antioxidative activity of about 80% Respectively.
또한, 식물 복합추출물:해조류 복합추출물의 혼합비율이 6:1 또는 85:1일 경우 항산화 활성이 낮은 것을 확인하였다.
Also, it was confirmed that the antioxidative activity was low when the mixing ratio of the plant complex extract: seaweed complex was 6: 1 or 85: 1.
시험예 2. 동물실험Test Example 2. Animal experiment
본 시험은 수컷 SD rat에게 7일 동안 실험물질을 공급한 후 알코올성 위장질환을 유도하며 시험물질인 실시예 7의 조성물을 액상 또는 고상 형태로 경구투여 한 후, 궤양 인덱스(Ulcer index) 측정, 혈장 내 히스타민(Histamine), 가스트린(Gastrin), 위 조직 내 IL-1β, TNF-α 농도를 측정하여 시험물질이 알코올성 위장질환의 개선 효과를 평가하고자 실시하였다. This test was conducted in male SD rats for 7 days after induction of alcoholic gastrointestinal disease. After oral administration of the composition of Example 7 as a liquid or solid form, ulcer index measurement, plasma Histamine, Gastrin, IL-1β and TNF-α levels in the stomach tissues were measured to evaluate the improvement effect of alcoholic gastrointestinal diseases.
200~230 g의 Sprague-Dawley 랫트(오리엔트바이오, Korea, 숫컷)를 실험에 사용하였다. 폴리카보네이트제 케이지(280W X 420D X 180H mm)에서 사육되었으며, 충분한 사료와 물이 공급되며 적절한 인공조도로 12시간의 낮, 밤을 조절하였다(am 7:00부터 낮). 그리고 일정한 온도(20~24 ℃) 및 습도(40~60%)를 유지시켜 주었다. 바뀐 환경에 적응하도록 일주일간 살펴보며 수면주기를 유지하고, 이상행동을 확인하였다. 또한, 식이로는 사울사료의 실험동물용 고형사료를 이용하였다.200-230 g of Sprague-Dawley rats (Orient Bio, Korea, male) were used in the experiment. The animals were housed in a polycarbonate cage (280W X 420D X 180H mm), fed with sufficient feed and water, and adjusted for 12 hours of daytime and night with appropriate artificial illumination (from 7 am onwards). It maintained a constant temperature (20 ~ 24 ℃) and humidity (40 ~ 60%). We observed for a week to adjust to the changed environment, maintained the sleep cycle, and confirmed abnormal behavior. As a diet, a solid feed for experimental animals of a sole diet was used.
실험동물은 체중변화가 일정하고 건강한 동물만을 선별하여 임의 배치법에 의해 생리식염수를 투여한 정상군, 에탄올+생리식염수 음성 대조군, 에탄올+실시예 7의 추출물을 액상으로 200 mg/kg 투여한 시료 투여군, 에탄올+실시예 7의 추출물을 고상으로 200 mg/kg으로 투여한 시료 투여군 및 에탄올+Ranitidine(광동제약) 50 mg/kg으로 투여한 양성 대조군으로 나누었으며 실험군마다 6마리씩 사용하였다. The experimental animals were divided into a normal group in which physiological saline was administered according to a random arrangement with a constant weight change and healthy animals, a negative control group of ethanol + physiological saline, ethanol + a sample administered with 200 mg / kg of the extract of Example 7 , Ethanol + the extract of Example 7 at a dose of 200 mg / kg as a solid phase, and a positive control group administered with ethanol + Ranitidine (Guangdong Pharmaceutical) at a dose of 50 mg / kg.
이때 시험물질을 일회용 주사기를 이용하여 투여 개시일부터 1일 1회, 7일 동안 총 7회 위 내에 강제 투여하였다.At this time, the test substance was forcibly administered in a disposable syringe 7 times a day for 7 days once a day from the start of administration.
실시예 7의 추출물은 액상으로 200 mg/kg 및 고상으로 200 mg/kg을 식염수에 녹여 4 ml/kg 경구 투여하였으며, Ranitidine 역시 50 mg/kg을 식염수에 녹여 4 ml/kg 경구 투여하였다.The extract of Example 7 was orally administered at a dose of 200 mg / kg in a liquid phase and 200 mg / kg in a solid phase at a dose of 4 ml / kg, and Ranitidine was dissolved in saline at a dose of 4 ml / kg.
-5개 군의 마우스--5 mice -
정상군: 생리식염수 7일 투여 6마리Normal group: 6 mice given saline solution for 7 days
음성 대조군: 에탄올 및 생리식염수 7일 투여 6마리Negative control group: Ethanol and saline solution for 6 days for 7 days
실시예 7(액상): 에탄올 및 실시예 7의 추출물(액상) 7일 투여 6마리Example 7 (Liquid Phase): Ethanol and the extract of Example 7 (liquid phase) 7 days Administration Six dogs
실시예 7(고상): 에탄올 및 실시예 7의 추출물(고상) 7일 투여 6마리Example 7 (solid phase): Ethanol and extract of Example 7 (solid phase) 7 days administration Six dogs
양성 대조군: 에탄올 및 Ranitidine 7일 투여 6마리
Positive control: 6 rats of ethanol and Ranitidine for 7 days
효능평가Efficacy evaluation
시험물질 투여 6일날 시험동물을 24시간 이상 절식시킨 후 시험물질을 투여하고 30분 후 무수 에탄올 10 ml/kg(음성 대조군, 투여군(액상), 투여군(고상), 양성 대조군)을 경구 투여한 이후 절식, 절수하여 1시간 방치한 다음 에테르로 마취하여 위를 적출하였다. 위의 대만부를 절개하여 펼친 후 사진촬영하고 냉동 보관하였다. 이미지 프로그램을 사용하여 위궤양(출혈부위) 길이를 측정한 후 궤양 인덱스(Ulcer index)(mm)로 표시하였다(점상출혈인 경우 5개를 1 mm로 계산).After the test animals were fasted for more than 24 hours on the 6th day of the test substance administration, the test substance was administered and oral administration of
동물을 희생하기에 앞서 복부대동맥에서 혈액을 체취하여 EDTA가 처리된 튜브에 넣고 롤러에서 5분 동안 반응시킨 후 3,000 rpm에서 20분 동안 원심분리하여 혈장을 체취하고 췌위한 혈장은 ??20 ℃에서 보관하며 시험에 사용하였다.Before sacrificing animals, blood was taken from the abdominal aorta, placed in EDTA-treated tubes, reacted for 5 minutes on a roller, centrifuged at 3,000 rpm for 20 minutes to collect plasma, and plasma for pancreas was stored at -20 ° C And stored for testing.
상기 혈장 내 히스타민(Histamine), 가스트린(Gastrin); 위 조직 내 IL-1β, TNF-α 농도는 각각의 ELISA Kit 메뉴얼대로 분석하였다.Histamine in the plasma, Gastrin; IL-1β and TNF-α concentrations in stomach tissues were analyzed according to the respective ELISA Kit manuals.
위 손상을 시키는 요인으로 알코올 과다섭취는 위에 위산의 분비와 출혈, 염증발생을 유발시켜 급성위궤양을 일으킨다.As a cause of gastric injuries, excessive alcohol intake causes gastric acid secretion, hemorrhage, inflammation and causes acute gastric ulcer.
위산 분비의 경로 중 히스타민(Histamine), 가스트린(Gastrin)의 활성은 위벽세포를 자극시켜 결국 위산의 분비를 증가시켜 위장 점막의 손상을 일으키게 된다. 또한, 위 조직의 손상으로 조직 내 염증이 유발되면 염증성 사이토카인 IL-1β, TNF-α가 증가하게 된다.
The activity of histamine and gastrin in the pathway of gastric acid secretion stimulates the gastric wall cells, which in turn increases the secretion of gastric acid and causes gastric mucosal damage. In addition, inflammation of the stomach due to damage to the stomach causes inflammatory cytokines such as IL-1β and TNF-α.
2-1. 궤양 인덱스(Ulcer index) 측정2-1. Ulcer index measurement
도 1은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 궤양 인덱스를 나타낸 그래프이며; 도 2는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군을 촬영한 사진이다.1 is a graph showing the ulcer indexes of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention; FIG. 2 is a photograph of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
도 1에 도시된 바와 같이, 음성 대조군의 UI는 평균 24.67 mm로, 정상군에 비하여 통계적으로 유의하게 증가하였다. As shown in FIG. 1, the UI of the negative control group was 24.67 mm, which was statistically significantly higher than that of the normal group.
또한, 실시예 7(액상)의 UI는 평균 13.52 mm이며, 실시예 7(고상)의 UI는 평균 14.28 mm로서, 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.In addition, the UI of Example 7 (liquid phase) was 13.52 mm on average, and the UI of Example 7 (solid phase) was 14.28 mm on average, which was statistically lower than that of negative control.
또한, 양성 대조군의 UI는 평균 13.78 mm로서, 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.The mean UI of the positive control group was 13.78 mm, which was statistically significantly lower than that of the negative control group.
또한 도 2에 도시된 바와 같이, 음성 대조군는 출혈부위가 다수 관찰되었으나 실시예 7(액상), 실시예 7(고상) 및 양성 대조군은 출혈부위가 관찰되지 않거나 적은 부위로 관찰되었다.
As shown in FIG. 2, the bleeding sites were observed in the negative control group, but the bleeding sites were not observed or observed in Example 7 (liquid phase), Example 7 (solid phase) and the positive control group.
2-2. 혈장 내 히스타민(Histamine) 농도2-2. Histamine concentration in plasma
도 3은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 히스타민(Histamine) 농도를 나타낸 그래프이다.FIG. 3 is a graph showing the histamine concentrations of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
도 3에 도시된 바와 같이, 정상군의 혈액 중 히스타민(Histamine) 농도는 평균 21.26 ng/ml이며, 음성 대조군의 혈액 중 히스타민(Histamine) 농도는 26.14 ng/ml로 정상군에 비하여 증가하였으나 통계학적으로 유의한 차이가 나타나지 않았다.As shown in FIG. 3, histamine (Histamine) concentration in the normal group was 21.26 ng / ml, and the histamine concentration in the negative control group was 26.14 ng / ml, There was no significant difference.
또한, 실시예 7(액상)의 혈액 중 히스타민(Histamine) 농도는 25.37 ng/ml이며, 실시예 7(고상)의 혈액 중 히스타민(Histamine) 농도는 24.11 ng/ml로서, 음성 대조군에 비하여 차이를 보이지 않았다.The histamine concentration in the blood of Example 7 (liquid phase) was 25.37 ng / ml, and the concentration of histamine in the blood of Example 7 (solid phase) was 24.11 ng / ml, I did not see it.
또한, 양성 대조군의 혈액 중 히스타민(Histamine) 농도는 19.22 ng/ml로서, 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.
Histamine concentration in the blood of the positive control group was 19.22 ng / ml, which was statistically lower than that of the negative control group.
2-3. 혈장 내 가스트린(Gastrin) 농도2-3. Plasma Gastrin concentration
도 4는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 가스트린(Gastrin) 농도를 나타낸 그래프이다.FIG. 4 is a graph showing the concentration of Gastrin in the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
도 4에 도시된 바와 같이, 정상군의 혈액 중 가스트린(Gastrin) 농도는 평균 211.30 pg/ml이며, 음성 대조군의 혈액 중 가스트린(Gastrin) 농도는 345.87 pg/ml로 정상군에 비하여 통계학적으로 유의하게 증가하였다.As shown in FIG. 4, the average concentration of gastrin in the blood of the normal group was 211.30 pg / ml, and the concentration of gastrin in the blood of the negative control group was 345.87 pg / ml, which was statistically significant Respectively.
또한, 실시예 7(액상)의 혈액 중 가스트린(Gastrin) 농도는 282.38 pg/ml로서, 음성 대조군에 비하여 감소하였으나 통계학적으로 차이가 나타나지 않았다.In addition, the concentration of gastrin in the blood of Example 7 (liquid phase) was 282.38 pg / ml, which was lower than that of negative control but not statistically different.
또한, 실시예 7(고상)의 혈액 중 가스트린(Gastrin) 농도는 270.15 pg/ml이며, 양성 대조군의 혈액 중 가스트린(Gastrin) 농도는 242.42 pg/ml로서, 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.
In addition, the concentration of gastrin in the blood of Example 7 (solid phase) was 270.15 pg / ml, and the concentration of gastrin in the blood of the positive control group was 242.42 pg / ml, which was statistically decreased Respectively.
2-4. 위 조직 내 IL-1β 농도2-4. IL-1β levels in stomach tissues
도 5는 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 IL-1β 농도를 나타낸 그래프이다.FIG. 5 is a graph showing the IL-1? Concentrations in the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
도 5에 도시된 바와 같이, 정상군의 위 조직 내 IL-1β 농도는 평균 194.64 pg/mg protein이며, 음성 대조군의 위 조직 내 IL-1β 농도는 276.68 pg/mg protein로 정상군에 비하여 통계학적으로 유의하게 증가하였다.As shown in FIG. 5, the IL-1β concentration in the stomach tissues of the normal group was 194.64 pg / mg protein and the IL-1β concentration in the stomach tissues of the negative control group was 276.68 pg / Respectively.
또한, 실시예 7(액상)의 위 조직 내 IL-1β 농도는 평균 220.97 pg/mg protein이며, 실시예 7(고상)의 위 조직 내 IL-1β 농도는 평균 224.91 pg/mg protein이고, 양성 대조군의 위 조직 내 IL-1β 농도는 평균 235.08 pg/mg protein으로서, 모두 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.
In addition, the IL-1? Concentration in the gastric tissues of Example 7 (liquid phase) was 220.97 pg / mg protein on average, the IL-1? Concentration in the stomach tissues of Example 7 (solid phase) was 224.91 pg / mg protein on average, The levels of IL-1β in the gastric tissues were 235.08 pg / mg protein, which was significantly lower than that of the negative control.
2-4. 위 조직 내 TNF-α 농도2-4. TNF-a concentration in stomach tissue
도 6은 본 발명의 정상군, 음성 대조군, 투여군(실시예 7_액상, 실시예 7_고상) 및 양성 대조군에 대한 TNF-α 농도를 나타낸 그래프이다.FIG. 6 is a graph showing the TNF-.alpha. Concentrations of the normal group, the negative control group, the administration group (Example 7 liquid phase, Example 7 solid phase) and the positive control group of the present invention.
도 6에 도시된 바와 같이, 정상군의 위 조직 내 TNF-α 농도는 평균 109.39 pg/mg protein이며, 음성 대조군의 위 조직 내 TNF-α 농도는 134.58 pg/mg protein로 정상군에 비하여 통계학적으로 유의하게 증가하였다.As shown in FIG. 6, the TNF-α concentration in the gastric tissues of the normal group was 109.39 pg / mg protein and the TNF-α concentration in the gastric tissues of the negative control group was 134.58 pg / Respectively.
또한, 실시예 7(액상)의 위 조직 내 TNF-α 농도는 평균 110.64 pg/mg protein로서, 음성 대조군에 비하여 통계학적으로 유의하게 감소하였다.In addition, the TNF-alpha concentration in the stomach tissues of Example 7 (liquid phase) was 110.64 pg / mg protein on average, which was statistically significantly lower than that of the negative control.
또한, 실시예 7(고상)의 위 조직 내 TNF-α 농도는 평균 130.57 pg/mg protein이고, 양성 대조군의 위 조직 내 TNF-α 농도는 평균 122.23 pg/mg protein으로서, 음성 대조군에 비하여 차이를 보이지 않았다.
In addition, the TNF-α concentration in the stomach tissues of Example 7 (solid phase) was 130.57 pg / mg protein on average and the TNF-α concentration in the stomach tissues of the positive control group was 122.23 pg / I did not see it.
2-9. 체중 측정2-9. Weight measurement
정상군의 체중은 투여개시일부터 투여 7일까지 평균 210.6-229.3 g의 변동을 나타내었으며, 음성 대조군의 체중은 평균 209.7-226.0 g의 변동을 나타내어 정상군에 비하여 통계학적으로 유의한 차이가 나타나지 않았다.The body weight of the normal group showed an average change of 210.6-229.3 g from the start of administration to the 7th day of administration, and the weight of the negative control group showed an average change of 209.7-226.0 g, which was not statistically different from that of the normal group .
또한, 실시예 7(액상)군의 체중, 실시예 7(고상)의 체중 및 양성 대조군의 체중은 각각 평균 210.4-227.5 g, 209.9-228.7 g 및 211.0-228.7 g으로서 음성 대조군과 통계학적으로 유의한 차이가 나타나지 않았다.
In addition, the body weight of the Example 7 (liquid) group, the body weight of Example 7 (solid) and the body weight of the positive control group were 210.4-227.5 g, 209.9-228.7 g and 211.0-228.7 g, respectively, There was no difference.
결론적으로, 수컷 SD rat에 시험물질을 투여한 후 알코올로 위궤양을 유도한 결과, 액상 및 고상(투여군) 모두 위궤양 유발억제를 보이는 것을 확인하였다. 또한, 위산분비를 활성화시키는 가스트린(Gastrin)의 경우 액상 및 고상의 시험물질을 투여 시 혈중 가스트린(Gastrin) 농도가 감소되는 것을 확인하였다. 염증성 지표인 IL-1β, TNF-α는 위 조직에서 액상 및 고상의 시험물질을 투여 시 감소하는 것을 보여 염증 유발을 억제시키는 것을 확인하였다.
In conclusion, the test substance was administered to male SD rats and the gastric ulcer was induced with alcohol. As a result, it was confirmed that both the liquid and solid phase (control group) showed gastric ulcer induction inhibition. In addition, in the case of gastrin which activates gastric acid secretion, it was confirmed that the blood gastrin concentration was decreased when the liquid and solid test substances were administered. IL-1β and TNF-α, which are inflammatory markers, decreased in the stomach tissues when administered with liquid and solid phase test substances, thus confirming the inhibition of inflammation induction.
하기에 본 발명의 분말을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.
제제예 1. 산제의 제조Preparation Example 1. Preparation of powder
실시예 7에서 얻은 추출물 분말 500 mg500 mg of the extract powder obtained in Example 7
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예 2. 정제의 제조Formulation Example 2. Preparation of tablets
실시예 7에서 얻은 추출물 분말 300 mg300 mg of the extract powder obtained in Example 7
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mgMagnesium stearate 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예 3. 캅셀제의 제조Formulation Example 3. Preparation of capsules
실시예 7에서 얻은 추출물 분말 200 mg200 mg of the extract powder obtained in Example 7
결정성 셀룰로오스 3 mgCrystalline cellulose 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예 4. 주사제의 제조Formulation Example 4. Preparation of injection
실시예 7에서 얻은 추출물 분말 600 mg600 mg of the extract powder obtained in Example 7
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4, 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플 당 상기의 성분 함량으로 제조한다.
It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.
제제예 5. 액제의 제조Formulation Example 5. Preparation of a liquid preparation
실시예 7에서 얻은 추출물 분말 4 g4 g of the extract powder obtained in Example 7
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100g으로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 g with purified water, To prepare a liquid agent.
제제예 6. 과립제의 제조Preparation Example 6 Preparation of Granules
실시예 7에서 얻은 추출물 분말 1,000 mg1,000 mg of the extract powder obtained in Example 7
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 과립제에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 과립제 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
The composition ratio of the above-mentioned vitamins and minerals is comparatively comparatively mixed with the granules according to the preferred embodiment. However, the blending ratio may be arbitrarily changed, and the above components are mixed according to the ordinary granule preparation method, Can be prepared and used in the manufacture of a health functional food composition according to a conventional method.
제제예 7. 기능성 음료의 제조Preparation Example 7. Preparation of functional beverage
실시예 7에서 얻은 추출물 분말 1,000 mg 1,000 mg of the extract powder obtained in Example 7
구연산 1,000 mgCitric acid 1,000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 mLPurified water was added to the flask to obtain a total of 900 mL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (7)
황칠 추출물 및 녹차 추출물을 포함하는 식물 복합추출물;을 포함하는 혼합물을 유효성분으로 함유하는 알코올성 위장질환의 예방 또는 치료용 약학 조성물.Extracts of seaweeds including Ganoderma lucidum extract, Mugwort extract, Mugwort extract, Mulberry leaf extract and Strawberry seaweed extract; And
A plant complex extract comprising an extract of a plant including green tea extract and a green tea extract as an active ingredient; and a pharmaceutical composition for preventing or treating an alcoholic gastrointestinal disorder.
황칠 추출물 및 녹차 추출물을 포함하는 식물 복합추출물;을 포함하는 혼합물을 유효성분으로 함유하는 알코올성 위장질환의 개선 또는 예방용 식품 조성물.Extracts of seaweeds including Ganoderma lucidum extract, Mugwort extract, Mugwort extract, Mulberry leaf extract and Strawberry seaweed extract; And
Wherein the composition contains a mixture comprising a plant extract of Huangchil and a green tea extract, as an active ingredient, for improving or preventing an alcoholic gastrointestinal disorder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170163116A KR101958969B1 (en) | 2017-11-30 | 2017-11-30 | A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170163116A KR101958969B1 (en) | 2017-11-30 | 2017-11-30 | A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101958969B1 true KR101958969B1 (en) | 2019-03-19 |
Family
ID=65908481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170163116A KR101958969B1 (en) | 2017-11-30 | 2017-11-30 | A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101958969B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102194653B1 (en) * | 2020-08-18 | 2020-12-24 | 주식회사 보삼바이오산업 | Method for manufacturing composition of health functional foods comprising extract of Salicomia herbacea L and Hijikia fusiforme as an effective ingredient for relieving hangover and composition using the same |
KR20220021237A (en) | 2020-08-13 | 2022-02-22 | 경상국립대학교산학협력단 | Composition for preventing and treating Bowel diseases caused by fine dust containing Ecklonia cava extract |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030044845A (en) * | 2001-11-29 | 2003-06-09 | 정주호 | Acetylcholinesterase inhibitor comprising extract of green tea and pharmaceutical preparation, food product and feed product containing the same |
KR20080039694A (en) * | 2006-11-01 | 2008-05-07 | 김종태 | Green tea composition comprising extract of siraitia grosvenori |
KR100842941B1 (en) * | 2007-05-04 | 2008-07-02 | 부경대학교 산학협력단 | Compound from capsosiphon fulvescens inhibiting injury of mucos membrane of stomach by alcohol and use thereof |
KR20100037865A (en) * | 2008-10-02 | 2010-04-12 | 부경대학교 산학협력단 | A composition for inhibiting gastric damages containing polysaccharide from hizikia fusiformis |
KR20110083985A (en) * | 2010-01-15 | 2011-07-21 | 한국생산기술연구원 | Mutant strain of brettanomyces custersii and method of ethanol production using the same |
KR101136059B1 (en) | 2008-12-02 | 2012-08-16 | 농업회사법인주식회사 무안황토명품고구마클러스터사업단 | Composition for suppressing alcoholic hangover and gastric ulcer by sweet potato fermentation fractions |
KR20160056007A (en) * | 2014-11-11 | 2016-05-19 | (주)디지탈옵틱 | Composition comprising extract of Dendropanax morbifera Lev. for the treatment and prevention of inflammatory disease |
KR20160138926A (en) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions |
KR101782848B1 (en) | 2016-12-16 | 2017-09-29 | 한국 한의학 연구원 | Composition for eliminating hangover and preventing, improving or treating alcoholic gastrointestinal diseases comprising Dolichos lablab extract as effective component |
-
2017
- 2017-11-30 KR KR1020170163116A patent/KR101958969B1/en active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030044845A (en) * | 2001-11-29 | 2003-06-09 | 정주호 | Acetylcholinesterase inhibitor comprising extract of green tea and pharmaceutical preparation, food product and feed product containing the same |
KR20080039694A (en) * | 2006-11-01 | 2008-05-07 | 김종태 | Green tea composition comprising extract of siraitia grosvenori |
KR100842941B1 (en) * | 2007-05-04 | 2008-07-02 | 부경대학교 산학협력단 | Compound from capsosiphon fulvescens inhibiting injury of mucos membrane of stomach by alcohol and use thereof |
KR20100037865A (en) * | 2008-10-02 | 2010-04-12 | 부경대학교 산학협력단 | A composition for inhibiting gastric damages containing polysaccharide from hizikia fusiformis |
KR101136059B1 (en) | 2008-12-02 | 2012-08-16 | 농업회사법인주식회사 무안황토명품고구마클러스터사업단 | Composition for suppressing alcoholic hangover and gastric ulcer by sweet potato fermentation fractions |
KR20110083985A (en) * | 2010-01-15 | 2011-07-21 | 한국생산기술연구원 | Mutant strain of brettanomyces custersii and method of ethanol production using the same |
KR20160056007A (en) * | 2014-11-11 | 2016-05-19 | (주)디지탈옵틱 | Composition comprising extract of Dendropanax morbifera Lev. for the treatment and prevention of inflammatory disease |
KR20160138926A (en) * | 2015-05-26 | 2016-12-06 | 연세대학교 산학협력단 | Composition for prevention, improvement or treatment of muscular disorder or improvement of muscular functions |
KR101782848B1 (en) | 2016-12-16 | 2017-09-29 | 한국 한의학 연구원 | Composition for eliminating hangover and preventing, improving or treating alcoholic gastrointestinal diseases comprising Dolichos lablab extract as effective component |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220021237A (en) | 2020-08-13 | 2022-02-22 | 경상국립대학교산학협력단 | Composition for preventing and treating Bowel diseases caused by fine dust containing Ecklonia cava extract |
KR102194653B1 (en) * | 2020-08-18 | 2020-12-24 | 주식회사 보삼바이오산업 | Method for manufacturing composition of health functional foods comprising extract of Salicomia herbacea L and Hijikia fusiforme as an effective ingredient for relieving hangover and composition using the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6345243B2 (en) | Enbu fermented food or beverage composition | |
KR101217080B1 (en) | Composition having herb extract as active incredient for treating hangover and preparation method thereof | |
KR101958969B1 (en) | A composition for improving, preventing and treating of alcoholic gastrointestinal diseases comprising a complex extract of seaweed and complex extract of plant | |
KR20140067826A (en) | Composition comprising sargassum fulvellum extract for preventing or treating inflammatory diseases | |
KR101118451B1 (en) | Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent] | |
KR102414431B1 (en) | A composition for improving, preventing and treating of diabetes mellitus | |
KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
KR102229547B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and Taraxacum platycarpum Dahlst | |
KR20190033828A (en) | Compositions for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising herbal extracts | |
KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
CN1907374A (en) | Chinese medicinal composition for treating oral disease | |
KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
KR101113603B1 (en) | Extract composition of herbal mixture for improving liver fucntion and relieving hangover | |
KR101237215B1 (en) | Phamaceutical composition for prevention or treatment of enteritis | |
KR101606773B1 (en) | Composition comprising oriental herbal extract for preventing or treating gastrointestinal disorder | |
KR102185011B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle | |
JPH0767576A (en) | Healthy edible material of mycelium | |
KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
KR101958975B1 (en) | A composition for improving, preventing and treating of fatty liver diseases comprising a complex extract of seaweed and complex extract of plant | |
KR0137897B1 (en) | Health food containing leaf of eucommia ulmoides oliver | |
KR20210074865A (en) | Pharmaceutical composition for preventing or treating diabetes, including extract of fermented tea leaves | |
KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
KR20190126565A (en) | A composition for improving, preventing and treating of pain containing oriental medicine herbs oil extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |